Promising combo for advanced blood cancer hits snag: trial ends early
NCT ID NCT03878199
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study looked at combining two drugs, ruxolitinib and CPX-351, to treat advanced stages of myeloproliferative neoplasms (MPN), a group of blood cancers. The goal was to find the best dose and see if the combo worked better than standard care for patients whose disease had progressed to leukemia. The trial was stopped early after enrolling only 12 people, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Simmons Cancer Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.